5. Characterizing the Drug Development Pipeline for Precision Medicines

Kapitel in diesem Buch

1. Frontmatter i
2. Contents vii
3. Acknowledgment ix
4. Introduction 1
5. 1. The Economic Value and Pricing of Personalized Medicine 9
6. 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS 21
7. 3. The Value of Pharmacogenomic Information 53
8. 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory 87
9. 5. Characterizing the Drug Development Pipeline for Precision Medicines 115
10. 6. Cost Sharing in Insurance Coverage for Precision Medicine 159
11. 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments 185
12. 8. Physicians’ Financial Incentives to Personalize Medicine 217
13. 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan 237
14. 10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger 273
15. 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies 305
16. Contributors 335
17. Author Index 339
18. Subject Index 345